key: cord-0687590-hyi4wb3y
authors: Garcia-Sanchez, Alvaro; Peña-Cardelles, Juan-Francisco; Ruiz, Steve; Robles, Flor; Ordonez-Fernandez, Esther; Salgado-Peralvo, Angel-Orión; Balloch, James; Simon, Jacob C.
title: Efficacy of Pre-Procedural Mouthwashes against SARS-CoV-2: A Systematic Review of Randomized Controlled Trials
date: 2022-03-18
journal: J Clin Med
DOI: 10.3390/jcm11061692
sha: 7a2305872a6d356e9285b7a3cc523bead5b48d6d
doc_id: 687590
cord_uid: hyi4wb3y

The oral mucosa is one of the first sites to be affected by the SARS-CoV-2. For this reason, healthcare providers performing aerosol-generating procedures (AGPs) in the oral cavity are at high risk of infection with COVID-19. The aim of this systematic review is to verify whether there is evidence in the literature describing a decrease in the salivary viral load of SARS-CoV-2 after using different mouthwashes. An electronic search of the MEDLINE database (via PubMed), Web of Science, SCOPUS, and the Cochrane library database was carried out. The criteria used were those described by the PRISMA(®) Statement. Randomized controlled trial studies that have used mouthwashes as a form of intervention to reduce the viral load in saliva were included. The risk of bias was analyzed using the Joanna Briggs Institute Critical Appraisal Tool. Ultimately, eight articles were included that met the established criteria. Based on the evidence currently available in the literature, PVP-I, CHX and CPC present significant virucidal activity against SARS-CoV-2 in saliva and could be used as pre-procedural mouthwashes to reduce the risk of cross-infection.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 was first discovered in December 2019 in Wuhan (China) followed by a rapid worldwide spread in a short duration of time [1] . This disease presented as an atypical pneumonia with the potential involvement of multiple body systems and organs [2] . As of 14 January 2022, there has been a total of 320,488,206 confirmed cases and 5,538,159 deaths worldwide [3] .

Evidence shows that SARS-CoV-2 can be transmitted by direct contact, droplets and fomites, and through airborne transmission [4] [5] [6] . Droplets of saliva have an important role in the transmission of the virus between people. These droplets are usually generated during activities, such as speech or coughing, and when inhaled, ingested or in direct contact with the mucosa, infection occurs [7, 8] .

The oral mucosa acts as a portal of entry by the virus [6] . SARS-CoV-2 can invade oral and salivary gland epithelium due to the great amounts of angiotensin converting enzyme 2 (ACE2) receptors in these locations [9] [10] [11] . The interaction between the spike protein 2 of 12 of the virus and the ACE2 receptors allows for the entry of the virus into cells [12] . This emphasizes the role of the oral cavity in the transmission of the virus.

For this reason, healthcare providers performing aerosol-generating procedures (AGPs) in the oral cavity are at high risk of infection with COVID-19 [13] . Most dental treatments are AGPs due to the use of ultrasonic devices, high-speed handpieces and 3-in-1 air-water syringes, among others. There are also numerous AGPs performed routinely in hospitals where airway manipulation is required. Since the onset of the pandemic, personal protective equipment (PPE) has been one of the most important measures to prevent transmission in healthcare facilities. In addition, pre-procedural rinses or mouthwashes have been proposed to reduce the viral load in saliva and to reduce the number of colony-forming units (CFUs) in aerosols [14, 15] . Moreover, various organizations recommend their use before dental treatments [16] [17] [18] .

The available literature includes various systematic reviews evaluating in vitro and in vivo studies. In the last few months, a significant number of randomized control trials (RCTs) investigating the efficacy of different mouthwashes against SARS-CoV-2 have published their results.

Therefore, the aim of this systematic review of RCTs was to evaluate the efficacy of different mouthwashes on the reduction of salivary viral load of SARS-CoV-2 in COVID-19 positive patients confirmed with RT-PCR tests as pre-procedural rinses.

The present review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA ® ) Statement [19, 20] . The protocol was registered at the International Prospective Register of Systematic Reviews (PROSPERO) under the registration number CRD42022303574.

This investigation was designed to answer the following PICO (P = patient/problem/ population; I = intervention; C = comparison; O = outcome) question based on the PRISMA ® guidelines.

In patients diagnosed with COVID-19 (P), does the use of pre-procedural mouthwashes (I) compared to not prescribing them (C) reduce the viral load present in saliva (O)? 

All the studies included were RCTs published in 2020 and 2021. There was a large discrepancy among the sample sizes of selected articles (ranged from 36 to 294). Due to the low number of studies available, it was decided that there would be no exclusion criteria set for a minimum number of participants. The total number of patients included within the studies was 851. All these patients were RT-PCR positive for SARS-CoV-2.

In these studies, rinsing times ranged between 30 s and 1 min. In the placebo group, distilled water [14, [22] [23] [24] [25] , saline [26] , and an unspecified inactive substance [27] were used. The control group in one study did not receive treatment [28] . In the test group several active compounds were used: CDCM ® (0.1% beta-cyclodextrin and 0.1% Citrox ® ) (n = 1 [14] ); hydrogen peroxide (HP) at 1% [25, 26] or 1.50% [22] ; chlorhexidine (CHX) at 0.12% [22, [25] [26] [27] [28] or 0.20% [23, 24] ; a combination of 0.12% CHX and 1.50% HP [22] ; cetylpyridinium chloride (CPC) 0.07% [25] and 0.075% [23] ; a combination of 0.075% CPC and 0.28% Zinc (Zn) [22] ; and povidone iodine (PVP-I) at 0.50% [23, 26] , 1% [24] and 2% [25] . All the studies investigated the effect of oral rinses, except for one article [28] which studied the combination of an oral rinse with an oropharyngeal spray. All saliva samples were evaluated through RT-PCR. Baseline samples were collected immediately before the intervention. The number of saliva samples after interventions varied among the studies. Two studies collected one sample of saliva after intervention [24, 28] , three collected two samples [22, 26, 27] , and three collected three samples [14, 23, 25] . A summary of the findings of the included articles are described in Table 1 . CPC + Zinc and CHX were effective in reducing the salivary viral load 60 min post-rinse. HP significantly reduced only at 30 min post-rinse. SARS-CoV-2 was eliminated from the oropharynx in 62.1% of patients who used CHX as an oral rinse, vs. 5.5% of the control group. In the combination group, 86.0% eliminated oropharyngeal SARS-CoV-2, vs. 6.3% of control patients.

Ferrer et al. [25] (2021) 84

RT-PCR at baseline, 30 , 60 and 120 min after mouthrinse Placebo (distilled water)/ 1 min.

2% PVP-I, 1% HP, 0.07% CPC, 0.12% CHX/ 1 min None of the mouthwashes evaluated presented a statistically significant change in the salivary viral load.

Costa et al. [27] (2021) 100

RT-PCR at baseline, 5 and 60 min after rinsing Placebo (inactive substance).

15 mL of 0.12% CHX/ 1 min.

There was a significant reduction in the salivary load at both 5 and 60 min after rinsing compared with the control. There was a reduction in the load of SARS-CoV-2 in 72% of the volunteers using chlorhexidine vs.

30% in the control group.

Seneviratne et al. [23] (2020) 36 Saliva samples for RT-PCR taken at baseline, 5 min, 3 and 6 h after rinse.

Placebo (water)/ 30 s. 0.5% PVP-I, 0.2% CHX, 0.075% CPC/30 s.

There were no differences in the reduction of salivary load in all intervention groups. When compared with the control group, PVP-I and CPC showed a significant reduction at 6 h. CPC also showed a significant reduction at 5 min.

The main findings of the articles are described below. Carrouel et al. [14] (2021) investigated the effects of a commercially available mouthwash containing CDCM ® on the reduction of the salivary viral load of SARS-CoV-2 versus (vs.) a placebo group (distilled water). A total of 176 patients with a confirmed diagnosis of COVID-19 were randomly assigned to the intervention or the control group. The patients rinsed three times a day for 7 days. Saliva sampling was performed before the first mouthwash and 1 h before the remaining two rinses. Saliva was then tested using RT-PCR. The use of this compound had a significant effect on reducing viral load 4 h after the initial dose, but the reduction was moderate at 7 days.

Eduardo et al. [22] (2021) recruited 60 patients and randomly allocated them into 5 groups: Placebo (distilled water), 0.075% CPC + 0.28% Zinc, 1.5% HP, 0.12% CHX and 1.50% HP + 0.12% CHX. Saliva samples for RT-PCR were collected at baseline, 30 and 60 min after rinse. CPC + Zinc and CHX resulted in significant reductions of the SARS-CoV-2 viral load in saliva up to 60 min after rinsing, while HP mouthwash resulted in a significant reduction up to 30 min after rinsing.

Chaudhary et al. [26] (2021) performed a randomized, triple-blinded study evaluating the effect of normal saline (placebo), 1% HP, 0.12% CHX and 0.50% PVP-I in 40 patients. Saliva samples for RT-PCR were collected at 15 and 45 min after rinsing. All 4 mouth rinses, including the placebo group, decreased viral load by 61-89% at 15 min and by 70-97% at 45 min.

Seneviratne et al. [23] (2020) evaluated the reduction in viral load using 0.50% PVP-I, 0.20% CHX, 0.075% CPC and placebo (distilled water) as mouthwashes. Saliva samples were taken for RT-PCR at baseline (pre-rinse), 5 min, 3 h and 6 h post-rinsing. Comparison of salivary Cycle threshold (Ct) values within all groups at 5 min, 3 h and 6 h did not show any significant differences. Compared with the control group (distilled water), a significant decrease in the viral load in the CPC group at 5 min and 6 h and in the PVP-I group at 6 h was observed.

Elzein et al. [24] (2021) recruited 61 patients with a confirmed diagnosis of COVID-19 who were randomly allocated into three groups: 1% PVP-I and 0.20% CHX as test groups and distilled water as the control group. Saliva samples were taken at baseline and 5 min post-rinse. A significant difference was noted between the delta Ct of distilled water wash and each of the test groups (0.20% CHX and 1% PVP-I). On the other hand, no significant difference was found between test groups.

Huang et al. [28] (2021) investigated 0.12% CHX as a mouthwash and as an oropharyngeal spray to reduce the viral load in saliva of SARS-CoV-2. Two hundred and ninety-four patients were recruited and randomly allocated into four groups: oral rinse only, oral rinse combined with oropharyngeal spray, and two control groups. The two control groups did not receive treatment. Oropharyngeal swabs were collected 4 days post-rinse for RT-PCR. SARS-CoV-2 was eliminated from the oropharynx in 62.1% of patients who used CHX as an oral rinse, vs. 5.50% of the control group. In the combination group, 86% eliminated oropharyngeal SARS-CoV-2, vs. 6.30% of control patients.

Ferrer et al. [25] (2021) investigated the reduction of the salivary load of SARS-CoV-2 in a sample of 80 patients randomly allocated into 5 groups: 2% PVP-I, 1% HP, 0.07% CPC, 0.12% CHX and control (distilled water). Saliva samples were taken at baseline, 30 min, 60 min and 120 min after the mouth rinse, and were evaluated through RT-PCR. There were no statistically significant changes in virucidal activity after the use of different mouthwashes compared with the control group.

Costa et al. [27] (2021) recruited 100 patients for a randomized double-blind control trial evaluating 0.12% CHX as a mouthwash vs. a control group (an inactive substance). Saliva samples were taken at baseline, 5 min and 60 min after rinsing, and were evaluated through RT-PCR. There was a significant reduction in the salivary viral load at both 5 min and 60 min after rinsing compared with the control group. Total reductions in the salivary viral load were 72% in the CHX group vs. 30% in the control group.

Using the JBI Critical Appraisal Tool for RCTs [21] , we established that one paper [28] had a low-quality assessment (0-7 domains) and seven papers [14, [22] [23] [24] [25] [26] [27] had a high-quality assessment (8-13 domains) . The analysis of the articles included is shown in Table 2 . e outcome assessors blind to treatment assignment? treatment groups treated identically other than the intervention of interest? s follow up complete and if not, were differences beups in terms of their follow-up adequately described and analyzed? re participants analyzed in the groups to which they were randomized? e outcomes measured in the same way for treatment groups?

Were outcomes measured in a reliable way?

. Was appropriate statistical analysis used?

the trial design appropriate and any deviations from d RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

.

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? .

Was follow up complete and if not, were differences beeen groups in terms of their follow-up adequately described and analyzed? .

Were participants analyzed in the groups to which they were randomized? . Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

. Was the trial design appropriate and any deviations from standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies 

SARS-CoV-2 is easily transmitted via droplets of sali ocular, nasal or oral mucosa, as well as through airborne performed in closed spaces. Not only the dental practitioner professionals involved in bronchoscopies, endoscopies, or i at higher risk of infection [29] . Rigorous infection control m settings, and pre-procedural mouthwashes could potentiall the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaq [30, 31] . In vitro studies demonstrated that it has virucidal a fluenza A [32] . In addition, it can reduce bacterial levels in a of CHX varied between 0.12% [22, [25] [26] [27] [28] e outcome assessors blind to treatment assignment? treatment groups treated identically other than the intervention of interest? s follow up complete and if not, were differences beups in terms of their follow-up adequately described and analyzed? re participants analyzed in the groups to which they were randomized? e outcomes measured in the same way for treatment groups?

Were outcomes measured in a reliable way?

. Was appropriate statistical analysis used?

the trial design appropriate and any deviations from d RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies

Carrouel et al. [14] Eduardo et al. [ Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

.

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? .

Was follow up complete and if not, were differences beeen groups in terms of their follow-up adequately described and analyzed? .

Were participants analyzed in the groups to which they were randomized? . Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

. Was the trial design appropriate and any deviations from standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies

Carrouel et al. [14] Eduardo et al. [ Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies

Carrouel et al. [14] Eduardo et al. [ Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies

Carrouel et al. [14] Eduardo et al. [ Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact wit ocular, nasal or oral mucosa, as well as through airborne transmission when AGP performed in closed spaces. Not only the dental practitioners are affected, but those h professionals involved in bronchoscopies, endoscopies, or intubations, among other at higher risk of infection [29] . Rigorous infection control methods are essential in cl settings, and pre-procedural mouthwashes could potentially be advantageous to dec the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis sol [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 an fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentra of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included stu CHX was the most predominant mouthwash present with seven out of the nine stu Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct con ocular, nasal or oral mucosa, as well as through airborne transmission wh performed in closed spaces. Not only the dental practitioners are affected, bu professionals involved in bronchoscopies, endoscopies, or intubations, amo at higher risk of infection [29] . Rigorous infection control methods are essen settings, and pre-procedural mouthwashes could potentially be advantageou the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingi [30, 31] . In vitro studies demonstrated that it has virucidal activity against H fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The c of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the incl CHX was the most predominant mouthwash present with seven out of the

Carrouel et al. [14] Eduardo et al. [ Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by d ocular, nasal or oral mucosa, as well as through airborne transmis performed in closed spaces. Not only the dental practitioners are affe professionals involved in bronchoscopies, endoscopies, or intubatio at higher risk of infection [29] . Rigorous infection control methods a settings, and pre-procedural mouthwashes could potentially be adv the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and a [30, 31] . In vitro studies demonstrated that it has virucidal activity a fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [1 of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among CHX was the most predominant mouthwash present with seven o

Carrouel et al. [14] Eduardo et al. [22] ( Chaudhary et al. [26] 1. Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of sali ocular, nasal or oral mucosa, as well as through airborne performed in closed spaces. Not only the dental practitioner professionals involved in bronchoscopies, endoscopies, or i at higher risk of infection [29] . Rigorous infection control m settings, and pre-procedural mouthwashes could potentiall the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaq [30, 31] . In vitro studies demonstrated that it has virucidal a fluenza A [32] . In addition, it can reduce bacterial levels in a of CHX varied between 0.12% [22, [25] [26] [27] [28] e outcome assessors blind to treatment assignment? treatment groups treated identically other than the intervention of interest? s follow up complete and if not, were differences beups in terms of their follow-up adequately described and analyzed? re participants analyzed in the groups to which they were randomized? e outcomes measured in the same way for treatment groups?

Were outcomes measured in a reliable way?

. Was appropriate statistical analysis used?

the trial design appropriate and any deviations from d RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

.

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? .

Was follow up complete and if not, were differences beeen groups in terms of their follow-up adequately described and analyzed? .

Were participants analyzed in the groups to which they were randomized? . Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

. Was the trial design appropriate and any deviations from standard RCT design accounted for in the conduct and analysis of the trial?

= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?

= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?

= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact wit ocular, nasal or oral mucosa, as well as through airborne transmission when AGP performed in closed spaces. Not only the dental practitioners are affected, but those h professionals involved in bronchoscopies, endoscopies, or intubations, among other at higher risk of infection [29] . Rigorous infection control methods are essential in cl settings, and pre-procedural mouthwashes could potentially be advantageous to dec the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis sol [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 an fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentra of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included stu CHX was the most predominant mouthwash present with seven out of the nine stu 1. Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?

= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact w ocular, nasal or oral mucosa, as well as through airborne transmission when AG performed in closed spaces. Not only the dental practitioners are affected, but those professionals involved in bronchoscopies, endoscopies, or intubations, among oth at higher risk of infection [29] . Rigorous infection control methods are essential in settings, and pre-procedural mouthwashes could potentially be advantageous to d the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis s [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 a fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concent of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included s CHX was the most predominant mouthwash present with seven out of the nine 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

6.

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?

= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by d ocular, nasal or oral mucosa, as well as through airborne transmis performed in closed spaces. Not only the dental practitioners are affe professionals involved in bronchoscopies, endoscopies, or intubatio at higher risk of infection [29] . Rigorous infection control methods a settings, and pre-procedural mouthwashes could potentially be adv the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and a [30, 31] . In vitro studies demonstrated that it has virucidal activity a fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [1 of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

6.

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?

= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of sali ocular, nasal or oral mucosa, as well as through airborne performed in closed spaces. Not only the dental practitioner professionals involved in bronchoscopies, endoscopies, or i at higher risk of infection [29] . Rigorous infection control m settings, and pre-procedural mouthwashes could potentiall the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaq [30, 31] . In vitro studies demonstrated that it has virucidal a fluenza A [32] . In addition, it can reduce bacterial levels in a of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24 CHX was the most predominant mouthwash present with 4. Were participants blind to treatment assignment? e outcome assessors blind to treatment assignment? treatment groups treated identically other than the intervention of interest? s follow up complete and if not, were differences beups in terms of their follow-up adequately described and analyzed? re participants analyzed in the groups to which they were randomized? e outcomes measured in the same way for treatment groups?

Were outcomes measured in a reliable way?

. Was appropriate statistical analysis used?

the trial design appropriate and any deviations from d RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

.

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? .

Was follow up complete and if not, were differences beeen groups in terms of their follow-up adequately described and analyzed? .

Were participants analyzed in the groups to which they were randomized? . Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

. Was the trial design appropriate and any deviations from standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

6.

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

6.

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?

= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact wit ocular, nasal or oral mucosa, as well as through airborne transmission when AGP performed in closed spaces. Not only the dental practitioners are affected, but those h professionals involved in bronchoscopies, endoscopies, or intubations, among other at higher risk of infection [29] . Rigorous infection control methods are essential in cl settings, and pre-procedural mouthwashes could potentially be advantageous to dec the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis sol [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 an fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentra of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included stu CHX was the most predominant mouthwash present with seven out of the nine stu Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?

= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct con ocular, nasal or oral mucosa, as well as through airborne transmission wh performed in closed spaces. Not only the dental practitioners are affected, bu professionals involved in bronchoscopies, endoscopies, or intubations, amo at higher risk of infection [29] . Rigorous infection control methods are essen settings, and pre-procedural mouthwashes could potentially be advantageou the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingi [30, 31] . In vitro studies demonstrated that it has virucidal activity against H fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The c of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the incl CHX was the most predominant mouthwash present with seven out of the Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by d ocular, nasal or oral mucosa, as well as through airborne transmis performed in closed spaces. Not only the dental practitioners are affe professionals involved in bronchoscopies, endoscopies, or intubatio at higher risk of infection [29] . Rigorous infection control methods a settings, and pre-procedural mouthwashes could potentially be adv the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and a [30, 31] . In vitro studies demonstrated that it has virucidal activity a fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [1 of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among CHX was the most predominant mouthwash present with seven o Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of sali ocular, nasal or oral mucosa, as well as through airborne performed in closed spaces. Not only the dental practitioner professionals involved in bronchoscopies, endoscopies, or i at higher risk of infection [29] . Rigorous infection control m settings, and pre-procedural mouthwashes could potentiall the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaq [30, 31] . In vitro studies demonstrated that it has virucidal a fluenza A [32] . In addition, it can reduce bacterial levels in a of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24 CHX was the most predominant mouthwash present with 5. Were those delivering treatment blind to treatment assignment? e outcome assessors blind to treatment assignment? treatment groups treated identically other than the intervention of interest? s follow up complete and if not, were differences beups in terms of their follow-up adequately described and analyzed? re participants analyzed in the groups to which they were randomized? e outcomes measured in the same way for treatment groups?

Were outcomes measured in a reliable way?

. Was appropriate statistical analysis used?

the trial design appropriate and any deviations from d RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

.

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? .

Was follow up complete and if not, were differences beeen groups in terms of their follow-up adequately described and analyzed? .

Were participants analyzed in the groups to which they were randomized? 0. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

. Was the trial design appropriate and any deviations from standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Table 2 . JBI Critical Appraisal Tool [21] for RCTs. Reprinted with permission from JBI. Copyright 2020.

1.

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Table 2 . JBI Critical Appraisal Tool [21] for RCTs. Reprinted with permission from JBI. Copyright 2020.

1.

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact wit ocular, nasal or oral mucosa, as well as through airborne transmission when AGP performed in closed spaces. Not only the dental practitioners are affected, but those h professionals involved in bronchoscopies, endoscopies, or intubations, among other at higher risk of infection [29] . Rigorous infection control methods are essential in cl settings, and pre-procedural mouthwashes could potentially be advantageous to dec the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis sol [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 an fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentra of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included stu CHX was the most predominant mouthwash present with seven out of the nine stu Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assign-ment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the in-tervention of interest?

Was follow up complete and if not, were differences be-tween groups in terms of their follow-up adequately described and analyzed?

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups? 11. Were outcomes measured in a reliable way? 12. Was appropriate statistical analysis used? 13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analy- 

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and In-fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by d ocular, nasal or oral mucosa, as well as through airborne transmis performed in closed spaces. Not only the dental practitioners are affe professionals involved in bronchoscopies, endoscopies, or intubatio at higher risk of infection [29] . Rigorous infection control methods a settings, and pre-procedural mouthwashes could potentially be adv the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and a [30, 31] . In vitro studies demonstrated that it has virucidal activity a fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [1 of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among CHX was the most predominant mouthwash present with seven o Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of sali ocular, nasal or oral mucosa, as well as through airborne performed in closed spaces. Not only the dental practitioner professionals involved in bronchoscopies, endoscopies, or i at higher risk of infection [29] . Rigorous infection control m settings, and pre-procedural mouthwashes could potentiall the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaq [30, 31] . In vitro studies demonstrated that it has virucidal a fluenza A [32] . In addition, it can reduce bacterial levels in a of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24 CHX was the most predominant mouthwash present with 6. Were outcome assessors blind to treatment assignment? able 2. JBI Critical Appraisal Tool [21] for RCTs. Reprinted with permission from JBI. Copyright 2020.

Carrouel et al. [ 

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Were participants blind to treatment assignment?

re those delivering treatment blind to treatment assignment?

ere outcome assessors blind to treatment assignment? e treatment groups treated identically other than the intervention of interest? as follow up complete and if not, were differences beroups in terms of their follow-up adequately described and analyzed? ere participants analyzed in the groups to which they were randomized? ere outcomes measured in the same way for treatment groups?

. Were outcomes measured in a reliable way?

2. Was appropriate statistical analysis used?

s the trial design appropriate and any deviations from ard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies J. Clin. Med. 2022, 11, x FOR PEER REVIEW 7 Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact wit ocular, nasal or oral mucosa, as well as through airborne transmission when AGP performed in closed spaces. Not only the dental practitioners are affected, but those h professionals involved in bronchoscopies, endoscopies, or intubations, among other at higher risk of infection [29] . Rigorous infection control methods are essential in cl settings, and pre-procedural mouthwashes could potentially be advantageous to dec the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis sol [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 an fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentra of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included stu CHX was the most predominant mouthwash present with seven out of the nine stu Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assign-ment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the in-tervention of interest?

Was follow up complete and if not, were differences be-tween groups in terms of their follow-up adequately described and analyzed?

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups? 11. Were outcomes measured in a reliable way? 12. Was appropriate statistical analysis used? 13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analy-sis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and In-fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies J. Clin. Med. 2022, 11, x FOR PEER REVIEW Table 2 . JBI Critical Appraisal Tool [21] for RCTs. Reprinted with permission from JBI. C

1.

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by d ocular, nasal or oral mucosa, as well as through airborne transmis performed in closed spaces. Not only the dental practitioners are affe professionals involved in bronchoscopies, endoscopies, or intubatio at higher risk of infection [29] . Rigorous infection control methods a settings, and pre-procedural mouthwashes could potentially be adv the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and a [30, 31] . In vitro studies demonstrated that it has virucidal activity a fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [1 of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among CHX was the most predominant mouthwash present with seven o 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by ocular, nasal or oral mucosa, as well as through airborne transm performed in closed spaces. Not only the dental practitioners are a professionals involved in bronchoscopies, endoscopies, or intubat at higher risk of infection [29] . Rigorous infection control methods settings, and pre-procedural mouthwashes could potentially be ad the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and [30, 31] . In vitro studies demonstrated that it has virucidal activity fluenza A [32] . In addition, it can reduce bacterial levels in aerosol of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] amon CHX was the most predominant mouthwash present with seven 7. Were treatment groups treated identically other than the intervention of interest? e outcome assessors blind to treatment assignment? treatment groups treated identically other than the intervention of interest? s follow up complete and if not, were differences beups in terms of their follow-up adequately described and analyzed? re participants analyzed in the groups to which they were randomized? e outcomes measured in the same way for treatment groups?

Were outcomes measured in a reliable way?

. Was appropriate statistical analysis used? the trial design appropriate and any deviations from d RCT design accounted for in the conduct and analysis of the trial?

= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies in. Med. 2022, 11, x FOR PEER REVIEW 7 of 12 Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

.

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? .

Was follow up complete and if not, were differences beeen groups in terms of their follow-up adequately described and analyzed? .

Were participants analyzed in the groups to which they were randomized? . Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

. Was the trial design appropriate and any deviations from standard RCT design accounted for in the conduct and analysis of the trial?

= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?

= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?

= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?

= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact wit ocular, nasal or oral mucosa, as well as through airborne transmission when AGP performed in closed spaces. Not only the dental practitioners are affected, but those h professionals involved in bronchoscopies, endoscopies, or intubations, among other at higher risk of infection [29] . Rigorous infection control methods are essential in cl settings, and pre-procedural mouthwashes could potentially be advantageous to dec the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis sol [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 an fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentra of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included stu CHX was the most predominant mouthwash present with seven out of the nine stu Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact w ocular, nasal or oral mucosa, as well as through airborne transmission when AG performed in closed spaces. Not only the dental practitioners are affected, but those professionals involved in bronchoscopies, endoscopies, or intubations, among oth at higher risk of infection [29] . Rigorous infection control methods are essential in settings, and pre-procedural mouthwashes could potentially be advantageous to d the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis s [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 a fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concent of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included s CHX was the most predominant mouthwash present with seven out of the nine Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?

= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by d ocular, nasal or oral mucosa, as well as through airborne transmis performed in closed spaces. Not only the dental practitioners are affe professionals involved in bronchoscopies, endoscopies, or intubatio at higher risk of infection [29] . Rigorous infection control methods a settings, and pre-procedural mouthwashes could potentially be adv the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and a [30, 31] . In vitro studies demonstrated that it has virucidal activity a fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [1 of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?

= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of sali ocular, nasal or oral mucosa, as well as through airborne performed in closed spaces. Not only the dental practitioner professionals involved in bronchoscopies, endoscopies, or i at higher risk of infection [29] . Rigorous infection control m settings, and pre-procedural mouthwashes could potentiall the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaq [30, 31] . In vitro studies demonstrated that it has virucidal a fluenza A [32] . In addition, it can reduce bacterial levels in a of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24 CHX was the most predominant mouthwash present with 8. Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? e outcome assessors blind to treatment assignment? treatment groups treated identically other than the intervention of interest? s follow up complete and if not, were differences beups in terms of their follow-up adequately described and analyzed? re participants analyzed in the groups to which they were randomized? e outcomes measured in the same way for treatment groups?

Were outcomes measured in a reliable way?

. Was appropriate statistical analysis used?

the trial design appropriate and any deviations from d RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

.

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? .

Was follow up complete and if not, were differences beeen groups in terms of their follow-up adequately described and analyzed? .

Were participants analyzed in the groups to which they were randomized? . Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

. Was the trial design appropriate and any deviations from standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . 

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . 

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . 

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact wit ocular, nasal or oral mucosa, as well as through airborne transmission when AGP performed in closed spaces. Not only the dental practitioners are affected, but those h professionals involved in bronchoscopies, endoscopies, or intubations, among other at higher risk of infection [29] . Rigorous infection control methods are essential in cl settings, and pre-procedural mouthwashes could potentially be advantageous to dec the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis sol [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 an fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentra of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included stu CHX was the most predominant mouthwash present with seven out of the nine stu Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assign-ment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the in-tervention of interest?

Was follow up complete and if not, were differences be-tween groups in terms of their follow-up adequately described and analyzed?

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups? 11. Were outcomes measured in a reliable way? 12. Was appropriate statistical analysis used? 13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analy- 

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and In-fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies J. Clin. Med. 2022, 11, x FOR PEER REVIEW 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by d ocular, nasal or oral mucosa, as well as through airborne transmis performed in closed spaces. Not only the dental practitioners are affe professionals involved in bronchoscopies, endoscopies, or intubatio at higher risk of infection [29] . Rigorous infection control methods a settings, and pre-procedural mouthwashes could potentially be adv the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and a [30, 31] . In vitro studies demonstrated that it has virucidal activity a fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [ 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.

Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?

11. Were outcomes measured in a reliable way?

12. Was appropriate statistical analysis used?

13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of sali ocular, nasal or oral mucosa, as well as through airborne performed in closed spaces. Not only the dental practitioner professionals involved in bronchoscopies, endoscopies, or i at higher risk of infection [29] . Rigorous infection control m settings, and pre-procedural mouthwashes could potentiall the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaq [30, 31] . In vitro studies demonstrated that it has virucidal a fluenza A [32] . In addition, it can reduce bacterial levels in a of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23,24 CHX was the most predominant mouthwash present with 9 . Were participants analyzed in the groups to which they were randomized? e outcome assessors blind to treatment assignment? treatment groups treated identically other than the intervention of interest? s follow up complete and if not, were differences beups in terms of their follow-up adequately described and analyzed? re participants analyzed in the groups to which they were randomized? e outcomes measured in the same way for treatment groups?

Were outcomes measured in a reliable way?

. Was appropriate statistical analysis used? the trial design appropriate and any deviations from d RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Were participants blind to treatment assignment?

re those delivering treatment blind to treatment assignment?

ere outcome assessors blind to treatment assignment? e treatment groups treated identically other than the intervention of interest? as follow up complete and if not, were differences beroups in terms of their follow-up adequately described and analyzed? ere participants analyzed in the groups to which they were randomized? ere outcomes measured in the same way for treatment groups?

. Were outcomes measured in a reliable way?

2. Was appropriate statistical analysis used?

s the trial design appropriate and any deviations from ard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.

CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies 

A Novel Coronavirus from Patients with Pneumonia in China

A Systematic Review of Systematic Reviews on the COVID-19 Pandemic. SN Compr

COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Coronavirus Pandemic (COVID-19

Particle Sizes of Infectious Aerosols: Implications for Infection Control

It Is Time to Address Airborne Transmission of Coronavirus Disease 2019 (COVID-19)

Transmission Routes of 2019-NCoV and Controls in Dental Practice

Salivary Diagnostics in COVID-19: Future Research Implications

A Rapid Advice Guideline for the Diagnosis and Treatment of 2019 Novel Coronavirus (2019-NCoV) Infected Pneumonia (Standard Version)

Antiviral Activity of Reagents in Mouth Rinses against SARS-CoV-2

Is There Scientific Evidence of the Mouthwashes Effectiveness in Reducing Viral Load in Covid-19? A Systematic Review

Insights to SARS-CoV-2 Life Cycle, Pathophysiology, and Rationalized Treatments That Target COVID-19 Clinical Complications

Structure Analysis of the Receptor Binding of 2019-NCoV

Dental Care during the Coronavirus Disease 2019 (COVID-19) Outbreak: Operatory Considerations and Clinical Aspects

COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression

Efficacy of Preprocedural Mouthrinses in the Reduction of Microorganisms in Aerosol

Guidance for Dental Practice

Covid-19-Portal/Cards/Misc/Critical-Information-For-SA-Members/COVID-19-Risk-Management-Guidance

American Dental Association ADA Interim Guidance for Minimizing Risk of COVID-19 Transmission

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P)

The Joanna Briggs Institute Checklist for Randomized Controlled Trials

Salivary SARS-CoV-2 Load Reduction with Mouthwash Use: A Randomized Pilot Clinical Trial

Efficacy of Commercial Mouth-Rinses on SARS-CoV-2 Viral Load in Saliva: Randomized Control Trial in Singapore

In Vivo Evaluation of the Virucidal Efficacy of Chlorhexidine and Povidone-Iodine Mouthwashes against Salivary SARS-CoV-2. A Randomized-Controlled Clinical Trial

Clinical Evaluation of Antiseptic Mouth Rinses to Reduce Salivary Load of SARS-CoV-2

Estimating Salivary Carriage of Severe Acute Respiratory Syndrome Coronavirus 2 in Nonsymptomatic People and Efficacy of Mouthrinse in Reducing Viral Load

Chlorhexidine Mouthwash Reduces the Salivary Viral Load of SARS-CoV-2: A Randomized Clinical Trial. Oral Dis. 2021

Use of Chlorhexidine to Eradicate Oropharyngeal SARS-CoV-2 in COVID-19 Patients

Structural Basis for the Recognition of SARS-CoV-2 by Full-Length Human ACE2

The Effect of Hexetidine Mouthwash on the Prevention of Plaque and Gingival Inflammation: A Systematic Review

Chlorhexidine Mouthrinse as an Adjunctive Treatment for Gingival Health

Virucidal Efficacy of Chlorhexidine: A Systematic Review

Chlorhexidine: An Effective Anticovid Mouth Rinse

Differential Effects of Antiseptic Mouth Rinses on SARS-CoV-2 Infectivity In Vitro

Effective in Vitro Inactivation of SARS-CoV-2 by Commercially Available Mouthwashes

Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2

Comparison of the In-Vitro Efficacy of Different Mouthwash Solutions Targeting SARS-CoV-2 Based on the European Standard EN 14476

Prevention of Respiratory Infections by Povidone-Iodine Gargle

In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens

Evaluation of the Bactericidal Activity of Povidone-Iodine and Commercially Available Gargle Preparations

Use of Povidone-Iodine during the First Trimester of Pregnancy: A Correct Practice?

Comparison of In Vitro Inactivation of SARS CoV-2 with Hydrogen Peroxide and Povidone-Iodine Oral Antiseptic Rinses

Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease

In Vitro Virucidal Activity of Povidone Iodine Gargle and Mouthwash against SARS-CoV-2: Implications for Dental Practice

Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)

Hydrogen Peroxide Inactivation of Influenza Virus Preserves Antigenic Structure and Immunogenicity

A Prospective Clinical Pilot Study on the Effects of a Hydrogen Peroxide Mouthrinse on the Intraoral Viral Load of SARS-CoV-2

Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19

Efficacy of Cetylpyridinium Chloride Used as Oropharyngeal Antiseptic

Virucidal Activity of Different Mouthwashes Using a Novel Biochemical Assay

Antimicrobial Activity of Citrox ® Bioflavonoid Preparations against Oral Microorganisms. Br

Virucidal Activity of Polysaccharide Extracts from Four Algal Species against Herpes Simplex Virus

Iota-Carrageenan Is a Potent Inhibitor of Influenza A Virus Infection

Iota-Carrageenan and Xylitol Inhibit SARS-CoV-2 in Vero Cell Culture

Data Availability Statement: Data available in a publicly accessible repository.

The authors declare no conflict of interest. J. Clin. Med. 2022, 11, 1692 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?.Were those delivering treatment blind to treatment assignment? 6 .Were outcome assessors blind to treatment assignment?.Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used? 13 . Was the trial design appropriate and any deviations from e standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies J. Clin. Med. 2022, 11, x FOR PEER REVIEW 7 of 12 Table 2 . JBI Critical Appraisal Tool [21] for RCTs. Reprinted with permission from JBI. Copyright 2020.

Carrouel et al. [14] (2021) Eduardo et al. [ 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment? 6 .Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used? 13 . Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies J. Clin. Med. 2022, 11, x FOR PEER REVIEW 7 of 12 Table 2 . JBI Critical Appraisal Tool [21] for RCTs. Reprinted with permission from JBI. Copyright 2020.

Carrouel et al. [14] (2021) Eduardo et al. [ 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment? 6 .Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used? 13 . Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assign-ment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the in-tervention of interest?

Was follow up complete and if not, were differences be-tween groups in terms of their follow-up adequately described and analyzed?

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups? 11. Were outcomes measured in a reliable way? 12. Was appropriate statistical analysis used? 13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analy-sis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and In-fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] 

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct co ocular, nasal or oral mucosa, as well as through airborne transmission w performed in closed spaces. Not only the dental practitioners are affected, b professionals involved in bronchoscopies, endoscopies, or intubations, am at higher risk of infection [29] . Rigorous infection control methods are esse settings, and pre-procedural mouthwashes could potentially be advantage the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigin [30, 31] . In vitro studies demonstrated that it has virucidal activity against fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the in CHX was the most predominant mouthwash present with seven out of t 

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by ocular, nasal or oral mucosa, as well as through airborne transm performed in closed spaces. Not only the dental practitioners are a professionals involved in bronchoscopies, endoscopies, or intubat at higher risk of infection [29] . Rigorous infection control methods settings, and pre-procedural mouthwashes could potentially be ad the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and [30, 31] . In vitro studies demonstrated that it has virucidal activity fluenza A [32] . In addition, it can reduce bacterial levels in aerosol of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] amon CHX was the most predominant mouthwash present with seven 10 . Were outcomes measured in the same way for treatment groups? e outcome assessors blind to treatment assignment? treatment groups treated identically other than the intervention of interest? s follow up complete and if not, were differences beups in terms of their follow-up adequately described and analyzed? re participants analyzed in the groups to which they were randomized? e outcomes measured in the same way for treatment groups?Were outcomes measured in a reliable way?. Was appropriate statistical analysis used?the trial design appropriate and any deviations from d RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?Were those delivering treatment blind to treatment assignment?.Were outcome assessors blind to treatment assignment?Were treatment groups treated identically other than the intervention of interest? .Was follow up complete and if not, were differences beeen groups in terms of their follow-up adequately described and analyzed? .Were participants analyzed in the groups to which they were randomized? . Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?. Was the trial design appropriate and any deviations from standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations J. Clin. Med. 2022, 11, x FOR PEER REVIEW 7 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact wit ocular, nasal or oral mucosa, as well as through airborne transmission when AGP performed in closed spaces. Not only the dental practitioners are affected, but those h professionals involved in bronchoscopies, endoscopies, or intubations, among other at higher risk of infection [29] . Rigorous infection control methods are essential in cl settings, and pre-procedural mouthwashes could potentially be advantageous to dec the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis sol [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 an fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentra J. Clin. Med. 2022, 11, x FOR PEER REVIEW 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct con ocular, nasal or oral mucosa, as well as through airborne transmission wh performed in closed spaces. Not only the dental practitioners are affected, bu professionals involved in bronchoscopies, endoscopies, or intubations, amo at higher risk of infection [29] . Rigorous infection control methods are essen settings, and pre-procedural mouthwashes could potentially be advantageou the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingi [30, 31] . In vitro studies demonstrated that it has virucidal activity against H fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The c J. Clin. Med. 2022, 11, x FOR PEER REVIEW 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by d ocular, nasal or oral mucosa, as well as through airborne transmis performed in closed spaces. Not only the dental practitioners are affe professionals involved in bronchoscopies, endoscopies, or intubatio at higher risk of infection [29] . Rigorous infection control methods a settings, and pre-procedural mouthwashes could potentially be adv the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and a [30, 31] . In vitro studies demonstrated that it has virucidal activity a fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [ 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of sali ocular, nasal or oral mucosa, as well as through airborne performed in closed spaces. Not only the dental practitioner professionals involved in bronchoscopies, endoscopies, or i at higher risk of infection [29] . Rigorous infection control m settings, and pre-procedural mouthwashes could potentiall the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaq [30, 31] . In vitro studies demonstrated that it has virucidal a fluenza A [32] . In addition, it can reduce bacterial levels in a 11. Were outcomes measured in a reliable way? e outcome assessors blind to treatment assignment? treatment groups treated identically other than the intervention of interest? s follow up complete and if not, were differences beups in terms of their follow-up adequately described and analyzed? re participants analyzed in the groups to which they were randomized? e outcomes measured in the same way for treatment groups?Were outcomes measured in a reliable way?. Was appropriate statistical analysis used?the trial design appropriate and any deviations from d RCT design accounted for in the conduct and analysis of the trial?= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis solution Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?Were those delivering treatment blind to treatment assignment?.Were outcome assessors blind to treatment assignment?Were treatment groups treated identically other than the intervention of interest? .Was follow up complete and if not, were differences beeen groups in terms of their follow-up adequately described and analyzed? .Were participants analyzed in the groups to which they were randomized? . Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?. Was the trial design appropriate and any deviations from standard RCT design accounted for in the conduct and analysis of the trial?= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis solution Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis solution Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis solution Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact wit ocular, nasal or oral mucosa, as well as through airborne transmission when AGP performed in closed spaces. Not only the dental practitioners are affected, but those h professionals involved in bronchoscopies, endoscopies, or intubations, among other at higher risk of infection [29] . Rigorous infection control methods are essential in cl settings, and pre-procedural mouthwashes could potentially be advantageous to dec the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis sol Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct con ocular, nasal or oral mucosa, as well as through airborne transmission wh performed in closed spaces. Not only the dental practitioners are affected, bu professionals involved in bronchoscopies, endoscopies, or intubations, amo at higher risk of infection [29] . Rigorous infection control methods are essen settings, and pre-procedural mouthwashes could potentially be advantageou the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingi Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by d ocular, nasal or oral mucosa, as well as through airborne transmis performed in closed spaces. Not only the dental practitioners are affe professionals involved in bronchoscopies, endoscopies, or intubatio at higher risk of infection [29] . Rigorous infection control methods a settings, and pre-procedural mouthwashes could potentially be adv the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and a Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of sali ocular, nasal or oral mucosa, as well as through airborne performed in closed spaces. Not only the dental practitioner professionals involved in bronchoscopies, endoscopies, or i at higher risk of infection [29] . Rigorous infection control m settings, and pre-procedural mouthwashes could potentiall the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaq 12 e outcome assessors blind to treatment assignment? treatment groups treated identically other than the intervention of interest? s follow up complete and if not, were differences beups in terms of their follow-up adequately described and analyzed? re participants analyzed in the groups to which they were randomized? e outcomes measured in the same way for treatment groups?Were outcomes measured in a reliable way?. Was appropriate statistical analysis used?the trial design appropriate and any deviations from d RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease in. Med. 2022, 11, x FOR PEER REVIEW 7 of 12 Table 2 . JBI Critical Appraisal Tool [21] for RCTs. Reprinted with permission from JBI. Copyright 2020.

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?Were those delivering treatment blind to treatment assignment?.Were outcome assessors blind to treatment assignment?Were treatment groups treated identically other than the intervention of interest? .Was follow up complete and if not, were differences beeen groups in terms of their follow-up adequately described and analyzed? .Were participants analyzed in the groups to which they were randomized? . Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?. Was the trial design appropriate and any deviations from standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease 

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease 

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease J. Clin. Med. 2022, 11, x FOR PEER REVIEW 7 

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact wit ocular, nasal or oral mucosa, as well as through airborne transmission when AGP performed in closed spaces. Not only the dental practitioners are affected, but those h professionals involved in bronchoscopies, endoscopies, or intubations, among other at higher risk of infection [29] . Rigorous infection control methods are essential in cl settings, and pre-procedural mouthwashes could potentially be advantageous to dec Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assign-ment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the in-tervention of interest?

Was follow up complete and if not, were differences be-tween groups in terms of their follow-up adequately described and analyzed?

Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups? 11. Were outcomes measured in a reliable way? 12. Was appropriate statistical analysis used? 13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analy-sis of the trial? 

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and In-fluenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies J. Clin. Med. 2022, 11, x FOR PEER REVIEW 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by d ocular, nasal or oral mucosa, as well as through airborne transmis performed in closed spaces. Not only the dental practitioners are affe professionals involved in bronchoscopies, endoscopies, or intubatio at higher risk of infection [29] . Rigorous infection control methods a settings, and pre-procedural mouthwashes could potentially be adv J. Clin. Med. 2022, 11, x FOR PEER REVIEW 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of sali ocular, nasal or oral mucosa, as well as through airborne performed in closed spaces. Not only the dental practitioner professionals involved in bronchoscopies, endoscopies, or i at higher risk of infection [29] . Rigorous infection control m settings, and pre-procedural mouthwashes could potentiall 13 . Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? e outcome assessors blind to treatment assignment? treatment groups treated identically other than the intervention of interest? s follow up complete and if not, were differences beups in terms of their follow-up adequately described and analyzed? re participants analyzed in the groups to which they were randomized? e outcomes measured in the same way for treatment groups?Were outcomes measured in a reliable way?. Was appropriate statistical analysis used?the trial design appropriate and any deviations from d RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed

Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?Were those delivering treatment blind to treatment assignment?.Were outcome assessors blind to treatment assignment?Were treatment groups treated identically other than the intervention of interest? .Was follow up complete and if not, were differences beeen groups in terms of their follow-up adequately described and analyzed? .Were participants analyzed in the groups to which they were randomized? . Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?. Was the trial design appropriate and any deviations from standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health J. Clin. Med. 2022, 11, x FOR PEER REVIEW 7 Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact wit ocular, nasal or oral mucosa, as well as through airborne transmission when AGP performed in closed spaces. Not only the dental practitioners are affected, but those h J. Clin. Med. 2022, 11, x FOR PEER REVIEW Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial?= yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact w ocular, nasal or oral mucosa, as well as through airborne transmission when AG performed in closed spaces. Not only the dental practitioners are affected, but those professionals involved in bronchoscopies, endoscopies, or intubations, among oth at higher risk of infection [29] . Rigorous infection control methods are essential in settings, and pre-procedural mouthwashes could potentially be advantageous to d Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by d ocular, nasal or oral mucosa, as well as through airborne transmis performed in closed spaces. Not only the dental practitioners are affe 

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assignment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the intervention of interest? 8.Was follow up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? 9.Were participants analyzed in the groups to which they were randomized? 10. Were outcomes measured in the same way for treatment groups?11. Were outcomes measured in a reliable way?12. Was appropriate statistical analysis used?13. Was the trial design appropriate and any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? = yes, = no, = uncertain.

SARS-CoV-2 is easily transmitted via droplets of sali ocular, nasal or oral mucosa, as well as through airborne performed in closed spaces. Not only the dental practitioner 7 

Was true randomization used for assignment of participants to treatment groups?

Was allocation to treatment groups concealed 3.Were treatment groups similar at the baseline?

Were participants blind to treatment assignment?

Were those delivering treatment blind to treatment assign-ment?

Were outcome assessors blind to treatment assignment?

Were treatment groups treated identically other than the in-tervention of interest?

Was follow up complete and if not, were differences be-tween groups in terms of their follow-up adequately described and analyzed?

Were participants analyzed in the groups to which they were randomized? 10 

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health = uncertain.

SARS-CoV-2 is easily transmitted via droplets of saliva by direct contact with the ocular, nasal or oral mucosa, as well as through airborne transmission when AGPs are performed in closed spaces. Not only the dental practitioners are affected, but those health professionals involved in bronchoscopies, endoscopies, or intubations, among others, are at higher risk of infection [29] . Rigorous infection control methods are essential in clinical settings, and pre-procedural mouthwashes could potentially be advantageous to decrease the risk of cross-infection between patients and personnel.CHX has been widely proven as an effective antiplaque and antigingivitis solution [30, 31] . In vitro studies demonstrated that it has virucidal activity against HSV-1 and Influenza A [32] . In addition, it can reduce bacterial levels in aerosol [15] . The concentrations of CHX varied between 0.12% [22, [25] [26] [27] [28] and 0.20% [23, 24] among the included studies. CHX was the most predominant mouthwash present with seven out of the nine studies including it as one of their intervention groups. The study by Costa et al. [27] found that there was a significant reduction (72%) in the salivary load at both 5 min and 60 min after rinsing compared with the control when 0.12% CHX was used. Three of the included studies demonstrated a significantly reduced viral load using 0.12% [22, 26] and 0.20% [28] concentrations compared with the control group. These findings are consistent with in vitro studies where the virucidal activity seen was >99.99% at a concentration of 0.20% and 99.99% at a concentration of 0.12% at both 30 s and 60 s contact times [33] . Xu et al. [34] had similar results, but the contact time was 30 min. On the other hand, the study by Ferrer et al. [25] found no statistically significant changes in viral load after the use of 0.12% CHX. Similar results have been obtained with in vitro studies, where the reduction of the viral load was not significant using 0.10% and 0.20% CHX [35] [36] [37] .PVP-I is composed of iodine and the water-soluble polymer polyvinylpyrrolidone. It has bactericidal and virucidal activity against MERS-CoV and influenza A, among others [38, 39] . The common use of PVP-I as a mouthwash has no deleterious health effects [40] . However, its use is contraindicated in patients allergic to iodine, thyroid disease and pregnancy [41] . During the initial stages of the pandemic, several associations recommended the use of pre-procedural 0.20% PVP-I mouth rinse to decrease the risk of SARS-CoV-2 transmission [16] [17] [18] . The concentrations of PVP-I in the included studies varied. Out of the 5 included studies that used PVP-I as a solution, two of them used 0.50% [24, 26] , one used 1% [28] and the last used 2% [25] . In general, the included studies demonstrate the efficacy of PVP-I to reduce the salivary load of SARS-CoV-2 [26, 28] .Seneviratne et al. [23] showed virucidal activity at 5 min and 3 h of post-rinsing with 0.5% PVP-I, but only a statistically significant increase at 6 h post-rinsing. Similar results have been reported in the literature. Multiple studies demonstrated virucidal activities of >4 log 10 at 15 [42] , 30 [43, 44] and 60 s [33, 45] of contact time. In contrast, the study by Ferrer et al. [25] showed no statistically significant changes in the viral load when using 2% PVP-I as a rinse.HP is a widely used antimicrobial agent and it is effective against several viruses including adenovirus, rhinovirus, myxovirus and influenza A [46] . Three studies included evaluated this solution at concentrations of 1% [25, 26] and 1.50% [22] . One of the included studies found that rinsing with HP resulted in a significant reduction of salivary viral load up to 30 min after rinsing, but the reduction at 60 min was not significant [22] . Similarly, the study by Chaudhary et al. [26] showed that the use of 1% HP mouthwash resulted in significant reductions of 80-89%, comparable to the other mouthwashes evaluated in the study (CHX, PVP-I). On the other hand, the study by Ferrer et al. [25] did not find statistically significant changes in salivary viral load after the use of the 1.50% HP mouthwash. An in vitro study reported log reductions of <1 at 30 s contact time using 1.50% HP. This reduction was significantly lower than all other mouthwashes studied (PVP-I, CHX, Ethanol + essential oils) [36] . Furthermore, a prospective clinical pilot study found that 1% HP does not reduce the intraoral viral load in SARS-CoV-2 positive patients [47] .CPC is a well-known, broad-spectrum quaternary ammonium used in over-thecounter mouthwashes with a rapid bactericidal effect on gram-positive pathogens and a fungicidal effect on yeasts in particular [48, 49] . The concentrations remained constant (0.075%) in the three articles included [22, 23, 25] . Seneviratne et al. [23] showed a significant reduction in viral load with the use of CPC mouthwash at 6 h, comparable with the reduction seen with PVP-I. Similarly, Eduardo et al. [22] found a significant reduction in viral load for up to 60 min after rinsing when using a combination of CPC + Zinc. Comparable results have been described in the literature. A study by Rodríguez-Casanovas et al. [50] evaluated a commercial mouthwash containing a combination of 0.05% CPC and 0.20% D-limonene. They observed a significant reduction of about 6 logs in the viral load compared with the control. J. Clin. Med. 2022, 11, 1692 9 of 12 CDCM ® is a commercially available mouthwash composed of Beta-cyclodextrin and Citrox ® . There was only one study included in this systematic review evaluating this compound [14] . They showed that the use of CDCM ® had a significant effect on reducing viral load 4 h after the initial dose but the reduction was moderate at 7 days. No other studies regarding the efficacy of this compound against SARS-CoV-2 have been published. However, a study on the efficacy of Citrox ® on reducing the oral microbiota concluded that Bioflavonoid preparations of Citrox ® have a broad spectrum of antimicrobial activity against oral microorganisms [51] .There are other solutions with a potential virucidal effect on SARS-CoV-2 in saliva. Two in vitro studies evaluated the efficacy of commercially available products containing essential oils (i.e., Listerine ® ) [34, 36] . They significantly reduced the viral titer (≥3.11 log 10), and they were as effective as PVP-I. Iota-Carrageenan (IC) is a derivative from red marine algae with virucidal activity that has been demonstrated in vitro against rhinovirus, herpesviruses and influenza A [52, 53] . An in vitro study by Bansal et al. [54] found that inhibitory concentrations are easily achievable by nasal and nebulization formulations which significantly reduced the viral load when compared with untreated controls. Nevertheless, further clinical studies are needed to demonstrate their efficacy and safety.

This systematic review presents several strengths, including an unrestricted search in the literature, data retrieval and risk assessment performed in duplicate.However, this review also presents some limitations. There was a large discrepancy in the number of participants in the studies included. Additionally, concentrations of the mouthwashes were not homogeneous in different studies. COVID-19 is a disease that is continuously being investigated, and multiple RCTs are evaluating the use of different mouthwashes in progress at this moment. Our results must be interpreted with caution until further investigations are carried out.

This study systematically reviewed the first RCTs performed on this topic. Further in vitro studies evaluating potential new molecules and additional RCTs are essential to demonstrate the safety and effectiveness of different mouthwashes.

Within the limitations of this study, PVP-I, CHX and CPC present significant virucidal activity against SARS-CoV-2 in saliva. A 30 s pre-procedural rinse of 0.50/1% PVP-I, 0.12/0.20% CHX, or 0.075% CPC could be beneficial to reduce the risk of cross-infection in healthcare settings performing AGPs.